Abu Dhabi’s TII and NVIDIA Launch Middle East’s First Joint ‘AI & Robotics’ NVAITC Research Lab
22.9.2025 11:34:00 CEST | Business Wire | Press Release
The Technology Innovation Institute (TII), the applied research arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), has joined forces with NVIDIA, the world leader in accelerated computing and AI, to launch the Middle East’s first Joint Lab dedicated to both artificial intelligence and robotics. This landmark collaboration establishes a first-of-its-kind hub in the region for developing next-generation AI models, robotics platforms, and humanoid technologies that will accelerate innovation across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922672333/en/
Abu Dhabi’s TII and NVIDIA Launch Middle East’s First Joint ‘AI & Robotics’ NVAITC Research Lab (Photo: AETOSWire)
The announcement of the TII-NVAITC (NVIDIA AI Technology Center) Joint Lab for AI and Robotics was made during a signing ceremony held at TII’s headquarters in Abu Dhabi, bringing together senior leaders from both organizations. The agreement was signed by Dr Najwa Aaraj, CEO of TII and Marc Domenech, Regional Director, Enterprise – META Region at NVIDIA, in the presence of H.E. Shahab Abu Shahab, Director General at ATRC, H.E. Abdulaziz Al Dosari, Executive Director of Support Services at ATRC, John Josephakis, Global VP of Sales and Business Development for HPC/Supercomputing at NVIDIA, and Simon See, Global Head NVIDIA AI Technology Centre at NVIDIA, marking a milestone moment in the UAE’s AI and robotics journey.
The collaboration places Abu Dhabi at the forefront of applied AI, aligning with the emirate’s long-term strategy to advance technological sovereignty and shape the future of intelligent autonomous systems. It also underscores the UAE’s growing role as a global AI and Robotics leader – highlighted by the recent US–UAE AI Acceleration Partnership – and positions the country as a major contributor to the global robotics ecosystem at a time when AI capabilities are rapidly evolving.
“This collaboration with NVIDIA marks a major step toward building AI-enhanced robotic systems capable of reasoning, adapting, and acting in complex environments,” said Dr. Najwa Aaraj, CEO of TII. “By combining our advanced robotic platforms with powerful AI models and compute, we are accelerating the convergence of perception, control, and language – laying the foundation for a new era of intelligent machines.”
The TII-NVAITC Joint Lab will integrate NVIDIA accelerated computing platforms and expertise with TII’s multidisciplinary research in AI, robotics, autonomous systems, and high-performance computing. It is the first NVAITC lab established in the Middle East, marking a significant milestone for the region. Together, the two organizations will accelerate the development of intelligent systems with real-world applications – advancing the field of Physical AI through embodied AI models, state-of-the-art robotics and humanoid stacks, and hardware designed for real-time robotic systems. Research will span robotic learning and control at scale, as well as the development and integration of large language models, including TII’s Falcon family of AI models – among them the Middle East’s first and largest AI models.
“The launch of the TII-NVAITC for AI and Robotics marks a new chapter in our global NVAITC network. By working with TII in Abu Dhabi, we are expanding the scope of these centers into robotics for the first time in the Middle East - helping researchers and innovators accelerate breakthroughs that will shape the future of intelligent systems,” said Carlo Ruiz, Vice President - Enterprise Solutions & Operations EMEA at NVIDIA.
This new lab forms part of TII’s broader strategy to advance applied AI and robotics that deliver real-world impact. At its core is a commitment to open innovation and global knowledge exchange, with TII and NVIDIA collaborating on research, open-source initiatives, and cross-network learning through the global NVAITC community. The lab also builds on TII’s existing modular robotic platforms and field-tested components, including robotic arms and delivery dogs, prioritizing research that is grounded in both technical excellence and practical readiness.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922672333/en/
Contacts
Jinan Warrayat,
+971504713552, jinan.warrayat@tii.ae
tii@edelman.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom